海创药业：HP515临床II期试验完成首批参与者入组

Core Viewpoint - The company has completed the enrollment of the first participants in the Phase II clinical trial of HP515, a drug developed for the treatment of Metabolic Associated Steatotic Liver Disease (MASH) [1] Group 1: Product Development - HP515 is an orally administered, highly selective THR-β agonist developed by the company [1] - The drug works by directly activating THR-β, which enhances downstream gene transcription [1] - HP515 aims to improve MASH by increasing lipid metabolism activity in liver cells, enhancing liver fat metabolism, and reducing lipotoxicity [1]